BUVIDAL MONTHLY buprenorphine 96 mg/0.27 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal monthly buprenorphine 96 mg/0.27 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 96 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

BUVIDAL MONTHLY buprenorphine 64 mg/0.18 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal monthly buprenorphine 64 mg/0.18 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 64 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

BUVIDAL WEEKLY buprenorphine 32 mg/0.64 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 32 mg/0.64 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 32 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL WEEKLY buprenorphine 24 mg/0.48 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 24 mg/0.48 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 24 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL WEEKLY buprenorphine 16 mg/0.32 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 16 mg/0.32 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 16 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL WEEKLY buprenorphine 8 mg/0.16 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal weekly buprenorphine 8 mg/0.16 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 8 mg - injection, solution - excipient ingredients: ethanol absolute; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal weekly is indicated for initiation and maintenance treatment of opioid dependence, with or without prior stabilisation on sublingual buprenorphine or buprenorphine/naloxone, within a framework of medical, social and psychological support.

BUVIDAL MONTHLY buprenorphine 160 mg/0.45 mL modified release solution for injection Australia - English - Department of Health (Therapeutic Goods Administration)

buvidal monthly buprenorphine 160 mg/0.45 ml modified release solution for injection

camurus pty ltd - buprenorphine, quantity: 160 mg - injection, solution - excipient ingredients: n-methyl-2-pyrrolidone; phosphatidyl choline; glyceryl dioleate; nitrogen - buvidal monthly is indicated for maintenance treatment of opioid dependence with prior stabilisation on buvidal weekly or sublingual buprenorphine or buprenorphine/naloxone within a framework of medical, social and psychological support.

Oral wound dressing, natural-polymer Australia - English - Department of Health (Therapeutic Goods Administration)

oral wound dressing, natural-polymer

btc speciality health pty ltd - 47943 - oral wound dressing, natural-polymer - episil? oral liquid is intended for the management and relief of pain in the oral cavity, soothing oral lesions of various origins, and for preventing the risk of painful inflammatory conditions of the mouth, such as oral mucositis/stomatitis.

BUVIDAL 128 MG Israel - English - Ministry of Health

buvidal 128 mg

blau pharmaceutical services ltd, israel - buprenorphine - prolong release solution for injection - buprenorphine 356 mg/ml - buprenorphine - treatment of opioid dependence within a framework of medical, social and psychological treatment.treatment is intended for use in adults and adolescents aged 16 years or over.

BUVIDAL 16 MG Israel - English - Ministry of Health

buvidal 16 mg

blau pharmaceutical services ltd, israel - buprenorphine - prolong release solution for injection - buprenorphine 50 mg/ml - buprenorphine - treatment of opioid dependence within a framework of medical, social and psychological treatment.treatment is intended for use in adults and adolescents aged 16 years or over.